AbbVie Inc.·4

Mar 1, 5:50 PM ET

Reents Scott T 4

4 · AbbVie Inc. · Filed Mar 1, 2024

Insider Transaction Report

Form 4
Period: 2024-02-23
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock, $0.01 par value

    2024-02-23$61.36/sh+14,140$867,63041,205 total
  • Sale

    Common Stock, $0.01 par value

    2024-02-23$177.44/sh14,140$2,509,00227,065 total
  • Tax Payment

    Common Stock, $0.01 par value

    2024-02-28$178.99/sh11,634$2,082,37015,431 total
  • Exercise/Conversion

    Option (Right to buy)

    2024-02-23$61.36/sh14,140$867,63017,380 total
    Exercise: $61.36From: 2018-02-16Exp: 2027-02-15Common Stock (14,140 underlying)
Footnotes (2)
  • [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.41 to $177.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Documents

1 file
  • 4
    form4-03012024_050325.xmlPrimary